In this randomized controlled trial, patients with metabolic syndrome who underwent time-restricted eating in addition to ...
The 5-year OS rate for pembrolizumab vs placebo was 86.1% vs 81.7% with HR 0.51 (significant). 2. Immune-mediated adverse ...
Patients in the semaglutide group reported fewer heart failure events than those in the placebo group. 2. No significant ...
Afami-cel (Tecelra) is the first genetically engineered T-cell receptor therapy for synovial sarcoma Afami-cel demonstrated ...
Ticagrelor was non-inferior to DAPT for the incidence of major adverse cardiovascular and cerebrovascular events. 2.
Afami-cel (Tecelra) is the first genetically engineered T-cell receptor therapy for synovial sarcoma Afami-cel demonstrated an overall response rate of... No ads & unlimited access to all current ...
1. Patients in the semaglutide group reported fewer heart failure events than those in the placebo group. 2. No significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback